Adoptive Transfer Aggravates B Cell Depletion Ameliorates whereas Its Response to Comment on ''Conventional B2

[1]  Xia Li,et al.  Regulatory T cells as a potent target for controlling bone loss. , 2010, Biochemical and biophysical research communications.

[2]  P. Tipping,et al.  Conventional B2 B Cell Depletion Ameliorates whereas Its Adoptive Transfer Aggravates Atherosclerosis , 2010, The Journal of Immunology.

[3]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[4]  Xia Li,et al.  The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. , 2010, Biochemical and biophysical research communications.

[5]  G. Kollias,et al.  Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis , 2010, The Journal of Immunology.

[6]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  James L Riley,et al.  Human T regulatory cell therapy: take a billion or so and call me in the morning. , 2009, Immunity.

[8]  P. Reichardt,et al.  Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies , 2008, PloS one.

[9]  A. Cope,et al.  Treg cells suppress osteoclast formation: a new link between the immune system and bone. , 2007, Arthritis and rheumatism.

[10]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[11]  M. Dougados,et al.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[12]  R. Gold,et al.  Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies , 2003, Journal of Neuroimmunology.

[13]  G. Hansson,et al.  Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. , 2002, The Journal of clinical investigation.

[14]  N. Ichimaru,et al.  Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases. , 2009, Cell transplantation.

[15]  G. Galbraith.  Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412Suntharalingam G, Perry MR, Ward S, et al (Northwick Park and St Mark's Hosp, London; Hammersmith Hosp, London; Imperial College, London) N Engl J Med 355:1018–1028, 2006§ , 2007 .

[16]  T. Hanke,et al.  CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells. , 2006, Autoimmunity reviews.